# US 2025/0084434 A1 · Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084434 A1
- Document ID: US20250084434A1
- Status: Published application
- Kind: A1
- Application number: 18/727,201
- Filed: 2023-01-09
- Published: 2025-03-13
- Earliest claimed: 2022-01-09
- Assignees: Kriya Therapeutics, Inc.
- Applicants: Kriya Therapeutics, Inc.
- Inventors: Michele STONE; Theresa HEAH; Nachiketa GUPTA; Weiran SHEN; Diana CEPEDA; Ruth CASTELLANOS
- Web page: https://patentgrep.com/patent/US20250084434A1

## CPC

- C12N 15/86: Viral vectors
- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- C07K 14/5428: {IL-10}
- C07K 14/55: IL-2
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/02: containing a signal sequence
- C07K 2319/50: containing protease site
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/007: cell or tissue specific
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides gene therapy vectors, antibody expression cassettes, and vectors comprising a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, delivery vectors (e.g., viral vectors) comprising gene therapy constructs a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, compositions comprising the same, and methods of using the same. Some aspects of the disclosure are directed to a recombinant adeno-viral vector (rAAV) particle for delivery of a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof.

## Claims

### Claim 1

A recombinant adeno-associated virus (rAAV) particle comprising a capsid and a vector genome, the vector genome comprising an inverted terminal repeat (ITR) and an antibody expression cassette, wherein the antibody expression cassette comprises (a) a promoter, (b) a nucleic acid sequence encoding a heavy chain variable region (VH) of an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody or an antigen-binding fragment thereof, and (c) a nucleic acid sequence encoding a light chain variable region (VL) of an anti-IGF-1R antibody or an antigen-binding fragment thereof.

### Claim 2 (depends on 1)

The rAAV particle of claim 1, wherein the nucleic acid sequence encoding the VH of the anti-IGF-1R antibody or an antigen-binding fragment thereof comprises (i) a nucleic acid encoding a VH complementary determining region (CDR) 1 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 7 or 10, (ii) a nucleic acid encoding a VH CDR2 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 8, 11 or 14, and (iii) a nucleic acid encoding a VH CDR3 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 9, 12 or 15; and the nucleic acid sequence encoding the VL of the anti-IGF-1R antibody or an antigen-binding fragment thereof comprises (i) a nucleic acid sequence comprising VL CDR1 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 16, (ii) a nucleic acid sequence comprising a VL CDR2 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 17, 20 or 23, and (iii) a nucleic acid sequence comprising a VL CDR3 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 18, 21 or 24.

### Claim 3

A vector comprising an antibody expression cassette comprising:
(a) a promoter;
(b) a nucleic acid sequence encoding a heavy chain variable region (VH) of an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody or an antigen-binding fragment thereof comprising (i) a nucleic acid encoding a VH complementary determining region (CDR) 1 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 7 or 10, (ii) a nucleic acid encoding a VH CDR2 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 8, 11 or 14, and (iii) a nucleic acid encoding a VH CDR3 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 9, 12 or 15; (c) a nucleic acid sequence encoding a light chain variable region (VL) of an anti-IGF-1R antibody or an antigen-binding fragment thereof comprising (i) a nucleic acid sequence comprising VL CDR1 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 16, (ii) a nucleic acid sequence comprising a VL CDR2 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 17, 20 or 23, and (iii) a nucleic acid sequence comprising a VL CDR3 comprising a nucleotide sequence with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 18, 21 or 24.

### Claim 4

The rAAV particle or the vector of any one of the previous claims, wherein the antibody expression cassette comprises a signal peptide.

### Claim 5

The rAAV particle or the vector of any one of the previous claims, wherein the antibody expression cassette comprises a linker sequence selected from an internal ribosome entry site (IRES) sequence, a proteolytic cleavage site, or a combination thereof.

### Claim 6 (depends on 5)

The rAAV particle or the vector of claim 5, wherein the proteolytic cleavage site comprises a furin cleavage site, a 2A cleavage site, or a combination thereof.

### Claim 7 (depends on 5)

The rAAV particle or the vector of claim 5, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the VH, the IRES, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 8 (depends on 5)

The rAAV particle or the vector of claim 5, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding the VH, the IRES, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 9 (depends on 5)

The rAAV particle or the vector of claim 5, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the VL, the IRES, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 10 (depends on 5, 6)

The rAAV particle or the vector of claim 5 or 6, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the VH, the proteolytic cleavage site, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 11 (depends on 5, 6)

The rAAV particle or the vector of claim 5 or 6, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding the VH, the proteolytic cleavage site, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 12 (depends on 5, 6)

The rAAV particle or the vector of claim 5 or 6, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the VL, the proteolytic cleavage site, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 13 (depends on 5, 6)

The rAAV particle or the vector of claim 5 or 6, wherein the antibody expression cassette comprises the promoter, the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding the VL, the proteolytic cleavage site, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 14 (depends on 4, 6, 7, 8, 9, 10)

The rAAV particle or the vector of any one of claim 4 or 6-10, wherein the IRES comprises a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43.

### Claim 15 (depends on 4, 5, 11, 12, 13, 14)

The rAAV particle or the vector of any one of claims 4-5 and 11-14, wherein the proteolytic cleavage comprises a furin cleavage site comprising a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44.

### Claim 16 (depends on 4, 5, 11, 149)

The rAAV particle or the vector of any one of claims 4-5 and 11-149, wherein the proteolytic cleavage comprises a 2A cleavage site comprising a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 45.

### Claim 17

The rAAV particle or the vector of any one of the previous claims, wherein the signal peptide is an IL-2 or an IL-10 signal peptide.

### Claim 18 (depends on 17)

The rAAV particle or the vector of claim 17, wherein the signal peptide comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119 or 120.

### Claim 19 (depends on 17, 18)

The rAAV particle or the vector of claim 17 or 18, wherein the signal peptide is encoded by a nucleotide sequences having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121 or 122.

### Claim 20

The rAAV particle or the vector of any one of the previous claims, wherein the antibody expression cassette comprises a second promoter.

### Claim 21 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the promoter (a first promoter), the nucleic acid sequence encoding the VL, the second promoter, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 22 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the promoter (a first promoter), the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding the VL, the second promoter, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 23 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the promoter (a first promoter), the nucleic acid sequence encoding the VH, the second promoter, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 24 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the promoter (a first promoter), the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding the VH, the second promoter, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 25 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the nucleic acid sequence encoding a VH, the promoter (a first promoter), the second promoter, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 26 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding a VH, the promoter (a first promoter), the second promoter, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VL in 5′-3′ orientation.

### Claim 27 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the nucleic acid sequence encoding a VL, the promoter (a first promoter), the second promoter, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 28 (depends on 20)

The rAAV particle or the vector of claim 20, wherein the antibody expression cassette comprises the nucleic acid sequence encoding the first signal peptide, the nucleic acid sequence encoding a VL, the promoter (a first promoter), the second promoter, the nucleic acid sequence encoding the second signal peptide, and the nucleic acid sequence encoding the VH in 5′-3′ orientation.

### Claim 29

The rAAV particle or the vector of any one of the previous claims, wherein the promoter and/or the second promoter is a constitutively active promoter, a cell-type specific promoter, a synthetic promoter, or an inducible promoter.

### Claim 30

The rAAV particle or the vector of any one of the previous claims, wherein the promoter and/or the second promoter is a CBA promoter, a CMV promoter (optionally, a human CMV promoter or a mouse CMV promoter), an EF1α promoter, a CAG promoter, or a tissue specific promoter.

### Claim 31

The rAAV particle or the vector of any one of the previous claims, wherein the promoter comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 47-51, 83, or 93.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The rAAV particle or the vector of any one of claims 1-30, wherein the promoter is a muscle specific promoter.

### Claim 33 (depends on 32)

The rAAV particle or the vector of claim 32, wherein the muscle specific promoter is selected from a desmin (DES) promoter, a human skeletal muscle α-actin (HSA) promoter, α myosin creatine kinase (MCK) promoter, a α myosin heavy chain myosine creatine kinase 7 (HMCK7) promoter, a dual MCK enhancer MCK (dMCK) promoter, a triple MCK enhancer MCK (tMCK) promoter, a dual MCK enhancer muscle-type creatine kinase 8 e (CK8e) promoter, a SPc5-12 promoter, a SP-301 promoter, a α myosin heavy chain (MHC) promoter, a Sk-CRM promoter, or a Sk-CRM4 promoter.

### Claim 34

The rAAV particle or the vector of any one of the previous claims, wherein the antibody expression cassette comprises an intron.

### Claim 35 (depends on 34)

The rAAV particle or the vector of claim 34, wherein the intron is a CAG intron, an SV40 intron, MVM intron, or a human beta-globin intron, or any combination thereof.

### Claim 36 (depends on 34, 35)

The rAAV particle or the vector of claim 34 or 35, wherein the intron comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NOs: 46 or 82.

### Claim 37

The rAAV particle or the vector of any one of the previous claims, wherein the promoter comprises a first and a promoter which are different.

### Claim 38 (depends on 37)

The rAAV particle or the vector of claim 37, wherein first and second promoter initiate transcription in the same direction.

### Claim 39 (depends on 37)

The rAAV particle or the vector of claim 37, wherein first and second promoter initiate transcription in different directions.

### Claim 40 (depends on 37)

The rAAV particle or the vector of claim 37, wherein the antibody expression cassette comprises a pause element between the first and second promoter.

### Claim 41 (depends on 40)

The rAAV particle or the vector of claim 40, wherein the pause element comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 54.

### Claim 42

The rAAV particle or the vector of any one of the previous claims, wherein the anti-IGF-1R antibody is a monoclonal antibody.

### Claim 43

The rAAV particle or the vector of any one of the previous claims, wherein the VH CDRs 1-3 correspond to the CDRs of teprotumumab.

### Claim 44

The rAAV particle or the vector of any one of the previous claims, wherein the VL CDRs 1-3 correspond to the CDRs of teprotumumab.

### Claim 45

The rAAV particle or the vector of any one of the previous claims, wherein the anti-IGF-1R antibody is teprotumumab.

### Claim 46

The rAAV particle or the vector of any one of the previous claims, wherein the nucleic acid sequence encoding the VH comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 25-27.

### Claim 47

The rAAV particle or the vector of any one of the previous claims, wherein the nucleic acid sequence encoding the VL comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 29-31.

### Claim 48

The rAAV particle or the vector of any one of the previous claims, wherein the nucleic acid sequence encoding the having chain (HC) comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 35-37.

### Claim 49

The rAAV particle or the vector of any one of the previous claims, wherein the nucleic acid sequence encoding the light chain (LC) comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 39-41.

### Claim 50

The rAAV particle or the vector of any one of the previous claims, wherein the anti-IGF-1R antibody is teprotumumab.

### Claim 51

The rAAV particle or the vector of any one of the previous claims, wherein the antibody expression cassette comprises a poly (A) sequence.

### Claim 52 (depends on 51)

The rAAV particle or the vector of claim 51, wherein the poly(A) sequence is selected from a bGHpA, a hGHpA, a SV40 pA, or a synthetic pA.

### Claim 53 (depends on 51, 52)

The rAAV particle or the vector of claim 51 or 52, wherein the poly (A) comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NOs: 52 or 53.

### Claim 54

The rAAV particle or the vector of any one of the previous claims, wherein antibody expression cassette comprises an open reading frame (ORF) comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 57-67 and 94-97.

### Claim 55

The AAV particle or the vector of any one of the previous claims, wherein the antibody expression cassette comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NOs: 68-76.

### Claim 56 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The vector of any one of claims 3-46 which comprises an inverted terminal repeats (ITR).

### Claim 57

The rAAV or the vector of any one of the previous claims, wherein the AAV ITR comprises a pair of ITRs flanking the antibody expression cassette.

### Claim 58 (depends on 48)

The rAAV particle or the vector of claim 48, wherein the ITRs are of the same serotype as one another.

### Claim 59 (depends on 49)

The rAAV particle or the vector of claim 49, wherein the ITRs are of the AAV2 serotype.

### Claim 60 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The vector of any one of claims 3-59, wherein the vector is packaged in an AAV capsid.

### Claim 61

The rAAV particle or the vector of any one of the previous claims, wherein AAV capsid serotype is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVRh8, AAVrh9, AAV9, AAVrh10, AAV10, AAV11, AAV12, and a modified version thereof.

### Claim 62

The rAAV particle or the vector of any one of the previous claims, wherein the AAV capsid serotype is selected from the group consisting of AAV1, AAV2, AAV6, AAV8, AAV9, and a modified version thereof.

### Claim 63

A host cell comprising the rAAV particle or the vector of any one of the previous claims.

### Claim 64

A composition comprising the rAAV particle or the vector of any one of the previous claims and a carrier.

### Claim 65 (depends on 64)

The composition of claim 64, wherein the carrier is water or saline.

### Claim 66

A method of expressing an anti-IGF-1R antibody or antigen-binding fragment thereof in a cell, comprising administering to the cell the rAAV particle, the vector, or the composition of any one of the previous claims, thereby expressing the anti-IGF-1R antibody or antigen-binding fragment thereof in the cell.

### Claim 67 (depends on 66)

The method of claim 66, wherein the cell is a fibroblast cell, an adipocyte cell, a myofibroblast cell, a myocyte cell, a muscle cell, or any combination thereof.

### Claim 68 (depends on 66, 67)

The method of claim 66 or 67, wherein the administration is in vitro.

### Claim 69 (depends on 66, 67)

The method of claim 66 or 67, wherein the administration is in vivo.

### Claim 70

A method of expressing an anti-IGF-1R antibody or antigen-binding fragment thereof in a subject in need thereof, comprising administering to the subject the rAAV particle, the vector, or the composition of any one of the previous claims, thereby expressing the anti-IGF-1R antibody or antigen-binding fragment thereof in the subject.

### Claim 71 (depends on 70)

The method of claim 70, wherein the subject suffers from a thyroid eye disease selected from active Graves' Orbitopathy and chronic Graves' Orbitopathy.

### Claim 72

A method of treating a thyroid eye disease in a subject in need thereof comprising administering to the subject the rAAV particle, the vector, or the composition of any one of the previous claims, thereby expressing the anti-IGF-1R antibody or antigen-binding fragment thereof in the subject and treating the thyroid eye disease.

### Claim 73 (depends on 72)

The method of claim 72, wherein the thyroid eye disease selected from active Graves' Orbitopathy and chronic Graves' Orbitopathy.

### Claim 74 (depends on 72, 73)

The method of any one of claims 72-73, wherein the administration is suitable for delivery of the rAAV particle or the vector to an ocular delivery site, a retro or a peri-orbital delivery site, a retrobulbar delivery site, an extra-ocular muscle delivery site, a connective tissue delivery site, or any combination of delivery sites thereof.

### Claim 75 (depends on 72, 73, 74)

The method of any one of claims 72-74, wherein the administration is by injection or infusion.

### Claim 76 (depends on 72, 73, 74, 75)

The method of any one of claims 72-75, wherein the administration is intramuscular (IM), intravenous (IV), intralymphatic, intraocular, retroorbital, periorbital, retrobulbar, or any combination thereof.

### Claim 77 (depends on 72, 73, 74, 75, 76)

The method of any one of claims 72-76, wherein the administration is suitable for delivery to retro or a peri-orbital fibroblast cells, adipocytes cells, myofibroblast cells, myocyte cells, or any combination thereof.

### Claim 78 (depends on 72, 73, 74, 75, 76, 77)

The method of any one of claims 72-77, wherein the administration is to an extra-ocular muscle.

### Claim 79 (depends on 78)

The method of claim 78, wherein the extra-ocular muscle is a levantor muscle or a glabellar muscle.

### Claim 80 (depends on 72, 73, 74, 75, 76, 77)

The method of any one of claims 72-77, wherein the administration is to a connective tissue.

### Claim 81 (depends on 72, 73, 74, 75, 76, 77)

The method of any one of claims 72-77, wherein administration is transconjunctival into the periorbital space.

### Claim 82 (depends on 72, 73, 74, 75, 76, 77)

The method of any one of claims 72-77, wherein the administration is intralymphatic comprising injection or infusion to the pre-auricular or submandibular node.

### Claim 83 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any one of claims 72-82, wherein the administration is a single dose.

### Claim 84 (depends on 83)

The method of claim 83, wherein the single dose multiple injections and/or infusions.
